Danaher to pay $4bn for Cepheid
Danaher Corp. is paying $4bn in cash ($53 per share, a 52% premium) to acquire fellow public firm Cepheid.
- In Vitro Diagnostics
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.